Edge Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Edge Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$216K	–	88
2025 Q4	$216K	Sell	10,000 -20,000	-67%	-$388K	0.04%	74
2025 Q3	$458K	Buy	30,000 +5,000	+20%	+$65.1K	0.08%	51
2025 Q2	$220K	Hold	25,000	–	–	0.04%	73
2025 Q1	$196K	Buy	25,000 +5,000	+25%	+$41.9K	0.04%	76
2024 Q4	$210K	Hold	20,000	–	–	0.04%	74
2024 Q3	$262K	Buy	+20,000	New	+$305K	0.05%	65
2024 Q2	–	Sell	-40,000	Closed	-$676K	–	79
2024 Q1	$676K	Sell	40,000 -110,000	-73%	-$1.64M	0.14%	42
2023 Q4	$2.12M	Hold	150,000	–	–	0.46%	29
2023 Q3	$1.54M	Hold	150,000	–	–	0.36%	33
2023 Q2	$2.47M	Sell	150,000 -20,000	-12%	-$260K	0.54%	32
2023 Q1	$1.55M	Hold	170,000	–	–	0.36%	33
2022 Q4	$1.19M	Buy	170,000 +14,000	+9%	+$98.2K	0.28%	39
2022 Q3	$795K	Hold	156,000	–	–	0.18%	43
2022 Q2	$381K	Buy	156,000 +11,000	+8%	+$45.2K	0.08%	58
2022 Q1	$990K	Hold	145,000	–	–	0.2%	48
2021 Q4	$1.17M	Hold	145,000	–	–	0.21%	47
2021 Q3	$1.42M	Buy	145,000 +15,000	+12%	+$118K	0.28%	50
2021 Q2	$881K	Hold	130,000	–	–	0.18%	57
2021 Q1	$1.18M	Buy	130,000 +30,000	+30%	+$243K	0.25%	53
2020 Q4	$679K	Buy	100,000 +40,000	+67%	+$250K	0.15%	62
2020 Q3	$302K	Buy	+60,000	New	+$437K	0.07%	88

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Edge Wealth Management's AVDL Position: Q1 2026 in Review

Edge Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,000 shares — an estimated $216K sold.

Edge Wealth Management first reported a position in AVDL in Q3 2020 and held it in 21 quarters. The position peaked at $2.47M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Edge Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Edge Wealth Management sold 10,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $216K.
Edge Wealth Management first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 21 quarters.
Edge Wealth Management's Avadel Pharmaceuticals position peaked at $2.47M in Q2 2023.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Edge Wealth Management's 13F filing for Q1 2026, filed 21 Apr 2026.